Thiogenesis Therapeutics, Corp.
TTIPF
$0.6468
$0.086815.50%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.29% | 32.96% | 2.45% | 3.21% | -5.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.92% | -32.36% | 18.92% | 45.48% | 68.62% |
| Operating Income | 18.92% | 32.36% | -18.92% | -45.48% | -68.62% |
| Income Before Tax | 21.18% | 38.86% | -17.89% | -43.64% | -70.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.18% | 38.86% | -17.89% | -43.64% | -70.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.18% | 38.86% | -17.89% | -43.64% | -70.17% |
| EBIT | 18.92% | 32.36% | -18.92% | -45.48% | -68.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 30.76% | 47.01% | -5.97% | -22.12% | -36.69% |
| Normalized Basic EPS | 30.81% | 47.06% | -7.26% | -23.59% | -38.27% |
| EPS Diluted | 30.76% | 47.01% | -5.97% | -22.12% | -36.69% |
| Normalized Diluted EPS | 30.81% | 47.06% | -7.26% | -23.59% | -38.27% |
| Average Basic Shares Outstanding | 12.59% | 15.92% | 17.08% | 21.24% | 26.98% |
| Average Diluted Shares Outstanding | 12.59% | 15.92% | 17.08% | 21.24% | 26.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |